A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.
Tomiyama T, Suzuki R, Harada N, Tamura T, Toshida K, Kosai-Fujimoto Y, Tomino T, Yoshiya S, Nagao Y, Takeishi K, Itoh S, Kobayashi N, Ito H, Yoshio S, Kanto T, Yoshizumi T, Fukuhara T.
Tomiyama T, et al. Among authors: kobayashi n.
Front Cell Infect Microbiol. 2023 May 16;13:1197349. doi: 10.3389/fcimb.2023.1197349. eCollection 2023.
Front Cell Infect Microbiol. 2023.
PMID: 37260700
Free PMC article.